115 related articles for article (PubMed ID: 22294579)
21. Advanced Techniques for Detection and Identification of Viral Contaminants Using the Ibis PLEX-ID Universal Biosensor.
Sampath R
PDA J Pharm Sci Technol; 2011; 65(6):690. PubMed ID: 22294599
[TBL] [Abstract][Full Text] [Related]
22. Contamination by porcine circovirus type 1: findings, investigations, and learnings.
Piérard I
PDA J Pharm Sci Technol; 2011; 65(6):614. PubMed ID: 22294584
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of a single-platform, rapid, nucleic Acid-based technology for detection of adventitious contaminants of cell culture.
Dehghani H; Lawrence B; Ill RC
PDA J Pharm Sci Technol; 2011; 65(6):675-80. PubMed ID: 22294596
[TBL] [Abstract][Full Text] [Related]
24. Adventitious Agents: Issues and Considerations during Pre-Approval Reviews and Inspections.
Eltermann J
PDA J Pharm Sci Technol; 2011; 65(6):694-7. PubMed ID: 22294603
[TBL] [Abstract][Full Text] [Related]
25. Regulatory approaches for control of viral contamination of vaccines.
McClenahan S; Uhlenhaut C; Krause PR
PDA J Pharm Sci Technol; 2011; 65(6):557-62. PubMed ID: 22294577
[TBL] [Abstract][Full Text] [Related]
26. Theory and practice of conventional adventitious virus testing.
Gregersen JP
PDA J Pharm Sci Technol; 2011; 65(6):634-44. PubMed ID: 22294590
[TBL] [Abstract][Full Text] [Related]
27. Chlorine dioxide remediation of a virus-contaminated manufacturing facility.
Lutgen M
PDA J Pharm Sci Technol; 2011; 65(6):620-4. PubMed ID: 22294587
[TBL] [Abstract][Full Text] [Related]
28. Detection of Latent Retroviruses in Vaccine-related Cell Substrates: Investigation of RT Activity Produced by Chemical Induction of Vero Cells.
Ma H; Khan AS
PDA J Pharm Sci Technol; 2011; 65(6):685-9. PubMed ID: 22294598
[TBL] [Abstract][Full Text] [Related]
29. Practicing safe cell culture: applied process designs for minimizing virus contamination risk.
Kiss RD
PDA J Pharm Sci Technol; 2011; 65(6):715-29. PubMed ID: 22294606
[TBL] [Abstract][Full Text] [Related]
30. Evolution of approaches to viral safety issues for biological products.
Lubiniecki AS
PDA J Pharm Sci Technol; 2011; 65(6):547-56. PubMed ID: 22294576
[TBL] [Abstract][Full Text] [Related]
31. Detection of adventitious viruses from biologicals using a broad-spectrum microbial detection array.
Jaing C; Gardner S; McLoughlin K; Thissen JB; Slezak T
PDA J Pharm Sci Technol; 2011; 65(6):668-74. PubMed ID: 22294595
[TBL] [Abstract][Full Text] [Related]
32. Application of Risk Assessments in the Design of the Overall Viral Control Strategy Used during the Manufacture and Testing of Live Virus Vaccines.
Pennathur S
PDA J Pharm Sci Technol; 2011; 65(6):730-6. PubMed ID: 22294607
[TBL] [Abstract][Full Text] [Related]
33. Adventitious Agent Risk Assessment Case Study: Evaluation of RotaTeq(R) for the Presence of Porcine Circovirus.
Ranucci CS; Tagmyer T; Duncan P
PDA J Pharm Sci Technol; 2011; 65(6):589-98. PubMed ID: 22294581
[TBL] [Abstract][Full Text] [Related]
34. Risk mitigation strategies for viral contamination of biotechnology products: consideration of best practices.
Rosenberg AS; Cherney B; Brorson K; Clouse K; Kozlowski S; Hughes P; Friedman R
PDA J Pharm Sci Technol; 2011; 65(6):563-7. PubMed ID: 22294578
[TBL] [Abstract][Full Text] [Related]
35. Mouse Minute Virus (MMV) Contamination--A Case Study: Detection, Root Cause Determination, and Corrective Actions.
Moody M; Alves W; Varghese J; Khan F
PDA J Pharm Sci Technol; 2011; 65(6):580-8. PubMed ID: 22294580
[TBL] [Abstract][Full Text] [Related]
36. Broadening our expectations for viral safety risk mitigation.
Kljavin IJ
PDA J Pharm Sci Technol; 2011; 65(6):645-53. PubMed ID: 22294591
[TBL] [Abstract][Full Text] [Related]
37. International scientific conference on viral safety and evaluation of viral clearance from biopharmaceutical products.14-16 June 1995, Bethesda, MD, USA.
Sanhueza S
Vaccine; 1996 Feb; 14(3):244-6. PubMed ID: 8920707
[No Abstract] [Full Text] [Related]
38. Report of the third conference on next-generation sequencing for adventitious virus detection in biologics for humans and animals.
Khan AS; Mallet L; Blümel J; Cassart JP; Knezevic I; Ng SHS; Wall M; Jakava-Viljanen M; Logvinoff C; Goios A; Neels P
Biologicals; 2023 Aug; 83():101696. PubMed ID: 37478506
[TBL] [Abstract][Full Text] [Related]
39. Report of the 2019 NIST-FDA workshop on standards for next generation sequencing detection of viral adventitious agents in biologics and biomanufacturing.
Cleveland MH; Anekella B; Brewer M; Chin PJ; Couch H; Delwart E; Huggett J; Jackson S; Martin J; Monpoeho S; Morrison T; Ng SHS; Ussery D; Khan AS
Biologicals; 2020 Mar; 64():76-82. PubMed ID: 32094072
[TBL] [Abstract][Full Text] [Related]
40. PDA/FDA Adventitious Agents and Novel Cell Substrates: Emerging Technologies and New Challenges, Nov. 3-4, 2011, Rockville, MD.
Khan AS; Lubiniecki A; King KE
PDA J Pharm Sci Technol; 2012; 66(6):502-11. PubMed ID: 23183646
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
